Pharma Focus Europe

Infant Bacterial Therapeutics' New Patent Receives Approval in Europe

Saturday, June 17, 2023

Infant Bacterial Therapeutics AB (IBT) has recently announced that the European Patent Office has granted approval for their patent application concerning Lactobacillus reuteri. This patent specifically pertains to their drug candidate, IBP-9414, which is currently in Phase III development. IBP-9414 aims to prevent Necrotizing Entercolitis (NEC) and promote sustained feeding tolerance (SFT) in premature infants.

The patent encompasses a unique method of activating freeze-dried bacteria, further solidifying the protection for IBT's drug candidate. Importantly, IBP-9414 has already been granted orphan drug status and data exclusivity for biological products in the United States and the European Union.

With a validity extending until 2036, the patent provides IBT with long-term protection and a competitive advantage. Once market authorization is obtained, IBT plans to launch IBP-9414 in the European market.

Staffan Strömberg, the CEO of IBT, expressed his satisfaction, stating, "We are pleased to have strengthened the intellectual property protection for IBP-9414 through the approval of this patent, particularly in a significant market like Europe."

Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024